Myocardial structural effects of aldosterone receptor antagonism in heart failure.

[1]  J. Sanderson,et al.  Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. , 2007, Journal of the American College of Cardiology.

[2]  Anne L. Taylor,et al.  Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. , 2007, Journal of cardiac failure.

[3]  J. Cohn.  Efficacy and safety in clinical trials in cardiovascular disease. , 2006, Journal of the American College of Cardiology.

[4]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[5]  J. McMurray,et al.  Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[6]  J. Cohn,et al.  The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. , 2004, European heart journal.

[7]  K. Weber,et al.  Aldosterone in Congestive Heart Failure , 2004 .

[8]  J. Cohn,et al.  Ventricular remodeling in heart failure: a credible surrogate endpoint. , 2003, Journal of cardiac failure.

[9]  P. Vandervoort,et al.  Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. , 2002, Journal of the American College of Cardiology.

[10]  J. Cohn.  The fallacy of the mean. , 2001, Journal of cardiac failure.

[11]  C. Delcayre,et al.  Cardiac aldosterone production and ventricular remodeling. , 2000, Kidney international.

[12]  J. Cohn,et al.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. , 2000, Journal of the American College of Cardiology.

[13]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[14]  J. Cohn,et al.  Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. , 1999, Journal of cardiac failure.

[15]  P. Grayburn,et al.  Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. , 1995, Journal of the American College of Cardiology.

[16]  C. Edwards,et al.  Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. , 1988, The Journal of clinical investigation.

[17]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[18]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .